The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Huang, Bo Yuan ^a   Zhan, Yi Ping ^a   Zong, Wen Jing ^a   Yu, Chun Jiang ^a   Li, Jun Fa ^a   Qu, Yan Ming ^a   Han, Song ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; LACTATE DEHYDROGENASE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, MOUSE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA STEM CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; T LYMPHOCYTE; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; CANCER STEM CELL; CELL LINE; GENETICS; GLIOMA; HUMAN; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL;

ANIMALS; ANTIGENS, CD274; CELL LINE; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84943194758     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134715     Document Type: Article

References (45)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classifiation of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMID: 17618441
2. Stupp R1, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5): 459-466. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895
3. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97: 2923-2931, 2001. PMID: 11342413
4. Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immuno-deficiency. J Immunol 153: 1687-1696, 1994. PMID: 7519209
5. Alvarez IB, Pasquinelli V, Jurado JO, Abbate E, Musella RM, de la Barrera SS. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis. 2010 Aug 15; 202(4):524-32. doi: 10.1086/654932 PMID: 20617899
6. Marcus A, Eshhar Z. Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer. Oncotarget. 2011; 2(7):525-526. PMID: 21719916
7. Miller JS. Biology of natural killer cells in cancer and infection. Cancer Invest. 2002; 20(3):405-419.
8. French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res Ther 2004; 6:8-14. PMID: 14979926
9. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007 May; 7(5):329-39. PMID: 17438573
10. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197-223. PMID: 11244035
11. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-95. PMID: 1396582
12. Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg 2012; 12:2575-87.
13. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T-cell stimulation, but only receptor ligation prevents T-cell activation. J Immunol 2004; 173: 945-954. PMID: 15240681
14. Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013; 288: 11771-11785. doi: 10.1074/jbc.M112.448126 PMID: 23417675
15. Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-3895. PMID: 1396582
16. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22: 265-268. PMID: 11323285
17. Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA. Arch Gynecol Obstet. 2014 Jan; 289(1):141-7. doi: 10.1007/s00404-013-2922-9 PMID: 23828443
18. Cunha LL, Marcello MA, Vassallo J, Ward LS. Differentiated thyroid carcinomas and their B7H1 shield. Future Oncol. 2013 Oct; 9(10):1417-9. doi: 10.2217/fon.13.89 PMID: 23651132
19. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84-88. PMID: 17159987
20. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-3175. doi: 10.1200/JCO.2009.26.7609 PMID: 20516446
21. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331 PMID: 18173375
22. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12. doi: 10.1016/j.coi.2011.12.009 PMID: 22236695
23. Ogbomo H, Zemp FJ, Lun X, Zhang J, Stack D, Rahman MM, et al. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS One. 2013 Jun 10; 8(6):e66825. doi: 10.1371/journal.pone.0066825 PMID: 23762498
24. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T. Autologous natural killer cell therapy forhuman recurrent malignant glioma. Anticancer Res. 2004 May-Jun; 24(3b):1861-71. PMID: 15274367
25. Zhang S, Xie R, Wan F, Ye F, Guo D, Lei T. Identifiation of U251 glioma stem cells and their heterogeneous stem-like phenotypes. Oncol Lett. 2013 Dec; 6(6):1649-1655. PMID: 24260059
26. Pak-Wittel MA, Piersma SJ, Plougastel BF, Poursine-Laurent J, Yokoyama WM.Isolation of murine natural killer cells.Curr Protoc Immunol. 2014 Apr 2; 105:3.22.1-9.
27. Mou X, Zhou Y, Jiang P, Zhou T, Jiang Q, Xu C. The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients. Sci Rep. 2014 Aug 20; 4:6138. doi: 10.1038/srep06138 PMID: 25138242
28. Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J. Immunother. 30: 789-797. PMID: 18049330
29. Jin J, Joo KM, Lee SJ, Jo MY, Kim Y, Jin Y. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep. 2011 Jan; 25(1):33-9. PMID: 21109954
30. Nam DH, Park K, Park C, Im YH, Kim MH, Lee S: Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 11: 263-268, 2004. PMID: 14719052
31. Arase H., Saito T., Phillips JH, Lanier LL. 2001. Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2). J. Immunol. 167, 1141. PMID: 11466327
32. Meinhardt K, Kroeger I, Abendroth A, Müller S, Mackensen A, Ullrich E. Influence of NK cell magnetic bead isolation methods on phenotype and function of murine NK cells. J Immunol Methods. 2012 Apr 30; 378(1-2):1-10. doi: 10.1016/j.jim.2012.01.008 PMID: 22306357
33. Kedmi M, Avigdor A, Nagler A. Anti-PD-1-Targeted Therapies Focusing on Lymphatic Malignancies: Biological Rationale, Clinical Challenges and Opportunities. Acta Haematol. 2014 Sep 20; 133(2): 129-135. doi: 10.1159/000362151 PMID: 25247668
34. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37:430-9. doi: 10.1053/j.seminoncol.2010.09.005 PMID: 21074057
35. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65. doi: 10.1056/NEJMoa1200694 PMID: 22658128
36. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54. doi: 10.1056/NEJMoa1200690 PMID: 22658127
37. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2014 Dec 6.
38. Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget. 2013 Sep; 4(9):1527-46. PMID: 24127551
39. Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C: Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol. 2012 Mar; 22(2):159-74. doi: 10.1111/j.1750-3639.2011.00515.x PMID: 21790828
40. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11:728-734. PMID: 15701862
41. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15:5379-5388. doi: 10.1158/1078-0432.CCR-09-0265 PMID: 19706802
42. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2014 Dec 6.
43. Jin J, Joo KM, Lee SJ, Jo MY, Kim Y, Jin Y. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep. 2011 Jan; 25(1):33-9. PMID: 21109954
44. Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K: Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27: 398-404, 2004. PMID: 15314549
45. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76: 840-852, 1995. PMID: 8625188